Next Article in Journal
Hypotension associated with Advanced Hodgkin Lymphoma
Previous Article in Journal
Decreased Threshold of Aggregation to Low-Dose Epinephrine is Evidence of Platelet Hyperaggregability in Patients with Thrombosis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Hematology Reports
Volume 6
Issue 3
10.4081/hr.2014.5195
hematolrep-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Safety and Efficacy of PDpoetin for Management of Anemia in Patients with End Stage Renal Disease on Maintenance Hemodialysis: Results from a Phase IV Clinical Trial

by
Abbas Norouzi Javidan
1,
Heshmatollah Shahbazian
2,
Amirhossein Emami
1,
Mir Saeed Yekaninejad
3,
Hassan Emami-Razavi
1,
Masoumeh Farhadkhani
1,
Ahmad Ahmadzadeh
4,* and
Fazel Gorjipour
5
1
Department of Physiology and Pharmacology, Brain and Spinal Injury Center, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
2
Division of Nephrology and Transplantation, Diabetic Research Center, Jondishapur University of Medical Sciences, Ahvaz, Iran
3
Department of Epidemiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
4
Health Research Institute, Research Centre of Thalassemia and Hemoglobinopathies, Ahvaz Jundishapur University of Medical Sciences, Golestan Avenue, Ahvaz, Iran
5
Physiology Research Center, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2014, 6(3), 5195; https://doi.org/10.4081/hr.2014.5195
Submission received: 24 November 2013 / Revised: 5 July 2013 / Accepted: 1 August 2013 / Published: 10 September 2014

Abstract

Recombinant human erythropoietin (rHuEPO) is available for correcting anemia. PDpoetin, a new brand of rHuEPO, has been certified by Food and Drug Department of Ministry of Health and Medical Education of Iran for clinical use in patients with chronic kidney disease. We conducted this post-marketing survey to further evaluate the safety and efficacy of PDpoetin for management of anemia in patients on maintenance hemodialysis. Patients from 4 centers in Iran were enrolled for this multicenter, open-label, uncontrolled phase IV clinical trial. Changes in blood chemistry, hemoglobin and hematocrit levels, renal function, and other characteristics of the patients were recorded for 4 months; 501 of the patients recruited, completed this study. Mean age of the patients was 50.9 (±16.2) years. 48.7% of patients were female. Mean of the hemoglobin value in all of the 4 centers was 9.29 (±1.43) g/dL at beginning of the study and reached 10.96 (±2.23) g/dL after 4 months and showed significant increase overall (p < 0.001). PDpoetin dose was stable at 50-100 U/kg thrice weekly. Hemorheologic disturbancesand changes in blood electrolytes was not observed. No case of immunological reactions to PDpoetin was observed. Our study, therefore, showed that PDpoetin has significantly raised the level of hemoglobin in the hemodialysis patients (about 1.7 ± 0.6 g/dL). Anemia were successfully corrected in 49% of patients under study. Use of this biosimilar was shown to be safe and effective for the maintenance of hemoglobin in patients on maintenance hemodialysis.
Keywords: kidney failure; chronic/complications; anemia/drug therapy; epoetin alfa; recombinant proteins; renal dialysis kidney failure; chronic/complications; anemia/drug therapy; epoetin alfa; recombinant proteins; renal dialysis

Share and Cite

MDPI and ACS Style

Norouzi Javidan, A.; Shahbazian, H.; Emami, A.; Yekaninejad, M.S.; Emami-Razavi, H.; Farhadkhani, M.; Ahmadzadeh, A.; Gorjipour, F. Safety and Efficacy of PDpoetin for Management of Anemia in Patients with End Stage Renal Disease on Maintenance Hemodialysis: Results from a Phase IV Clinical Trial. Hematol. Rep. 2014, 6, 5195. https://doi.org/10.4081/hr.2014.5195

AMA Style

Norouzi Javidan A, Shahbazian H, Emami A, Yekaninejad MS, Emami-Razavi H, Farhadkhani M, Ahmadzadeh A, Gorjipour F. Safety and Efficacy of PDpoetin for Management of Anemia in Patients with End Stage Renal Disease on Maintenance Hemodialysis: Results from a Phase IV Clinical Trial. Hematology Reports. 2014; 6(3):5195. https://doi.org/10.4081/hr.2014.5195

Chicago/Turabian Style

Norouzi Javidan, Abbas, Heshmatollah Shahbazian, Amirhossein Emami, Mir Saeed Yekaninejad, Hassan Emami-Razavi, Masoumeh Farhadkhani, Ahmad Ahmadzadeh, and Fazel Gorjipour. 2014. "Safety and Efficacy of PDpoetin for Management of Anemia in Patients with End Stage Renal Disease on Maintenance Hemodialysis: Results from a Phase IV Clinical Trial" Hematology Reports 6, no. 3: 5195. https://doi.org/10.4081/hr.2014.5195

APA Style

Norouzi Javidan, A., Shahbazian, H., Emami, A., Yekaninejad, M. S., Emami-Razavi, H., Farhadkhani, M., Ahmadzadeh, A., & Gorjipour, F. (2014). Safety and Efficacy of PDpoetin for Management of Anemia in Patients with End Stage Renal Disease on Maintenance Hemodialysis: Results from a Phase IV Clinical Trial. Hematology Reports, 6(3), 5195. https://doi.org/10.4081/hr.2014.5195

Article Metrics

Back to TopTop